Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Advance Realty Acquires Sanofi R&D Campus | Contract Pharma

What are you searching for?

Sign in
Breaking News

Advance Realty Acquires Sanofi R&D Campus

Offers lab, office, and GMP production space for local pharma

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

A joint venture partnership of Advance Realty and CrossHarbor Capital Partners, LLC has acquired the former Sanofi U.S. R&D Campus in Bridgewater, NJ. The site has 1.2 million sq. ft. of lab, office, and GMP production space, and is currently used by Amneal Pharmaceuticals and Ashland Specialty Ingredients. It will be branded as the NJ Center of Excellence.
 
“The former Sanofi U.S. R&D Campus is a jewel of Bridgewater and one of the most dynamic properties in the State of NJ,” Bridgewater Township Mayor Daniel J. Hayes, Jr., said. “The Garden State’s biotechnology and pharmaceutical industries are recognized national and international leaders, and this campus is surrounded by the type of highly skilled and educated workers that are integral to the success of these sectors. We look forward to working with Advance and CrossHarbor to fill the property with a vibrant mix of companies.”
 
Advance Realty, currently based in Bedminster, will relocate its headquarters to the campus, and is considering redeveloping a portion of the property for a mix of uses.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics